Glycemia reduction in type 2 diabetes - glycemic outcomes
Gu S, Wang W, Ye G, Chen C, Zhou Y, Guo L, et al
[1] [2] In clinical trials (SUSTAIN-6), semaglutide demonstrated cardiovascular benefits in patients with type 2 diabetes at high cardiovascular risk, though its licensed indication in the UK remains specifically for glycaemic control in type 2 diabetes
Ginger Vieira, author, speaker, podcast host, and type 1 diabetes advocate, has shared her personal experience with microdosing semaglutide as part of her diabetes management plan
They test their levels, identify specific deficiencies, source targeted supplements at therapeutic doses, and adjust based on results